mug11 Antibody

What is MYH11 and why is it significant in research applications?

MYH11 (Myosin Heavy Chain 11) is a protein encoded by the MYH11 gene in humans. This protein, also known as smooth muscle myosin heavy chain (SMMHC), is a critical structural component of the contractile apparatus in smooth muscle cells. With a molecular weight of approximately 227.3 kilodaltons, MYH11 serves as an important marker for smooth muscle differentiation in various research contexts . The significance of MYH11 extends to its role in vascular development, and mutations in this gene have been associated with certain aortic aneurysms and specific leukemias. In research applications, MYH11 antibodies provide valuable tools for investigating smooth muscle physiology, vascular pathologies, and cellular differentiation processes across multiple model systems including human, mouse, and rat specimens.

What are the primary research applications for MYH11 antibodies?

MYH11 antibodies are utilized across multiple experimental platforms in biomedical research. The primary applications include:

• Immunohistochemistry (IHC): For detection of MYH11 in paraffin-embedded tissue sections, particularly valuable in studies of vascular architecture and smooth muscle distribution .

• Western Blotting (WB): For quantitative assessment of MYH11 protein expression in tissue or cell lysates, allowing for comparative analysis across different experimental conditions .

• Immunofluorescence (IF): For visualization of MYH11 localization within cellular compartments, enabling co-localization studies with other proteins of interest .

• Flow Cytometry (FCM): For quantitative analysis of MYH11 expression at the single-cell level, particularly useful in heterogeneous cell populations .

• Immunoprecipitation (IP): For isolation of MYH11 and associated protein complexes to study protein-protein interactions .

These applications collectively enable comprehensive investigation of smooth muscle biology, vascular development, and related pathological conditions.

How should samples be prepared for optimal MYH11 detection?

Optimal detection of MYH11 requires careful consideration of sample preparation methodology. For tissue specimens intended for immunohistochemistry, fixation in 10% neutral buffered formalin for 24-48 hours followed by paraffin embedding is recommended. Antigen retrieval methods significantly impact MYH11 antibody performance; heat-induced epitope retrieval using citrate buffer (pH 6.0) typically yields superior results over EDTA-based buffers.

For protein extraction for Western blotting applications, RIPA buffer supplemented with protease inhibitors effectively solubilizes MYH11 while preserving its integrity. Given the high molecular weight of MYH11 (227.3 kDa), gel electrophoresis requires careful optimization—typically using 6-8% polyacrylamide gels with extended run times to achieve proper resolution .

For immunofluorescence applications, fixation with 4% paraformaldehyde for 15-20 minutes at room temperature, followed by permeabilization using 0.1-0.3% Triton X-100, provides optimal conditions for antibody penetration while preserving cellular architecture. When working with frozen tissue sections, acetone fixation for 10 minutes at -20°C often yields better results than formalin-based protocols.

What criteria should researchers consider when selecting a MYH11 antibody for specific applications?

Selecting the appropriate MYH11 antibody requires systematic evaluation of several critical parameters:

When selecting between rabbit polyclonal antibodies (such as HPA014539 from Atlas Antibodies) and mouse monoclonals, consider that polyclonals often provide greater epitope coverage but potentially increased background, while monoclonals offer higher specificity at potentially lower sensitivity .

How can researchers validate the specificity of a MYH11 antibody?

Comprehensive validation of MYH11 antibody specificity requires a multi-modal approach:

• Positive Control Tissues: Vascular smooth muscle in normal blood vessels provides an excellent positive control for MYH11 expression. Specifically, the media layer of arteries should show strong, consistent staining .

• Knockout/Knockdown Validation: The gold standard for specificity validation involves testing the antibody on tissues or cells where MYH11 expression has been genetically eliminated or substantially reduced (siRNA, CRISPR). Absence of signal in these samples confirms specificity.

• Peptide Competition Assay: Pre-incubation of the antibody with purified MYH11 protein or the immunizing peptide should abolish specific staining in subsequent applications.

• Western Blot Analysis: Verification that the antibody detects a band of appropriate molecular weight (approximately 227.3 kDa for full-length MYH11) without significant cross-reactive bands .

• Orthogonal Methods: Correlation of protein detection with mRNA expression data (qPCR or RNA-seq) from the same samples provides additional validation of specificity.

These approaches, used in combination, establish confidence in antibody specificity and minimize the risk of misleading experimental outcomes based on non-specific binding.

How should researchers design experiments to address potential cross-reactivity with other myosin isoforms?

MYH11 belongs to the myosin heavy chain family, which includes multiple isoforms with significant sequence homology. To address potential cross-reactivity concerns:

• Epitope Selection: Antibodies targeting unique regions of MYH11 minimize cross-reactivity. The non-helical tail domain contains sequences with lower homology to other myosin family members and typically offers greater specificity.

• Sequential Immunolabeling: For multiple myosin isoform detection in the same specimen, sequential rather than simultaneous immunolabeling with careful antibody stripping between rounds minimizes cross-detection issues.

• Comparative Analysis: Include parallel experiments with antibodies against other myosin isoforms (MYH9, MYH10) to establish differential expression patterns.

• Control Cell Lines: Utilize cell lines with established myosin isoform expression profiles as specificity controls. For example, certain smooth muscle cell lines highly express MYH11 while being negative for skeletal muscle-specific myosins.

• Absorption Controls: Pre-absorb antibodies with recombinant proteins representing potentially cross-reactive myosin isoforms to confirm specificity.

What are the optimal control samples for MYH11 antibody experiments?

Implementing appropriate controls is essential for reliable interpretation of MYH11 antibody experiments:

For optimal experimental design, positive and negative controls should be processed simultaneously with experimental samples to control for technical variables. When studying developmental processes or disease models, time-matched or condition-matched controls are essential for accurate comparative analysis.

What considerations should be made when using MYH11 antibodies in multiplex immunostaining protocols?

Multiplex immunostaining with MYH11 antibodies requires careful optimization to achieve reliable co-detection with other markers:

• Antibody Host Species Selection: Choose primary antibodies raised in different host species (e.g., rabbit anti-MYH11 combined with mouse anti-CD31) to enable simultaneous detection with species-specific secondary antibodies.

• Fluorophore Selection: When designing fluorescent multiplex panels, consider spectral overlap between fluorophores. For MYH11 (typically abundant in positive cells), pair with longer-wavelength fluorophores (e.g., Cy5) which generally have lower background, reserving brighter fluorophores (e.g., FITC) for less abundant targets.

• Sequential Immunostaining: For complex multiplex panels or when primary antibodies are from the same species, implement sequential staining with appropriate blocking and stripping steps between rounds.

• Antigen Retrieval Compatibility: Ensure all antibodies in the multiplex panel perform optimally under the same antigen retrieval conditions, as MYH11 detection typically requires heat-induced epitope retrieval.

• Cross-Blocking Validation: Verify that secondary antibodies do not cross-react with primary antibodies from different species, which would create false co-localization signals.

These considerations enable accurate characterization of MYH11 expression in relation to other markers, facilitating complex phenotypic analyses of tissue architecture and cellular relationships.

How can researchers optimize western blot protocols for high-molecular-weight MYH11 detection?

Detecting MYH11 (227.3 kDa) by western blot presents specific technical challenges requiring protocol optimization:

• Gel Composition: Use low percentage (6-7%) polyacrylamide gels to facilitate migration of high-molecular-weight proteins. Commercial gradient gels (4-15%) also provide effective separation.

• Transfer Conditions: Implement extended transfer times (overnight at low voltage, 30V) or utilize specialized transfer systems designed for high-molecular-weight proteins. Semi-dry transfer systems typically perform poorly with proteins >150 kDa.

• Protein Extraction: Use extraction buffers containing SDS or urea to ensure complete solubilization of myosin filaments. Standard RIPA buffer supplemented with protease inhibitors is generally effective for MYH11 extraction .

• Loading Controls: Traditional loading controls like β-actin (42 kDa) or GAPDH (37 kDa) may transfer differently than MYH11. Consider using total protein normalization methods (e.g., stain-free technology) or high-molecular-weight controls like vinculin (124 kDa).

• Blocking Optimization: Extended blocking (2 hours at room temperature or overnight at 4°C) with 5% non-fat dry milk or BSA reduces background in the high-molecular-weight range.

These optimizations substantially improve detection sensitivity and quantification accuracy for MYH11 in western blot applications.

What are the most common causes of false positive and false negative results when using MYH11 antibodies?

Understanding potential sources of erroneous results is crucial for accurate MYH11 detection:

Careful consideration of these factors and implementation of appropriate controls significantly improves reliability of MYH11 detection across experimental platforms.

How should researchers approach quantification of MYH11 expression in immunohistochemistry applications?

Quantitative analysis of MYH11 immunostaining requires systematic methodology:

• Digital Image Acquisition: Use standardized image acquisition parameters (exposure, gain, resolution) across all specimens. Capture multiple representative fields (minimum 5-10) per sample to account for tissue heterogeneity.

• Scoring Systems:

  • For manual assessment, implement a semiquantitative scoring system (0-3+) based on staining intensity

  • Consider H-score method (multiplying intensity score by percentage of positive cells) for more nuanced quantification

  • Document both staining intensity and distribution pattern (membranous, cytoplasmic, or filamentous)

• Automated Analysis:

  • Utilize image analysis software with tissue segmentation capabilities

  • Develop algorithms that can distinguish specific cell types based on morphology

  • Validate automated measurements against expert manual scoring

• Statistical Considerations:

  • Use appropriate statistical tests based on data distribution

  • Account for multiple testing when analyzing different tissue regions

  • Consider intra- and inter-observer variability assessments for manual scoring

• Reporting Standards:

  • Clearly describe quantification methodology in publications

  • Include representative images showing the range of staining patterns

  • Report both qualitative patterns and quantitative measurements

This comprehensive approach enables reliable comparative analysis of MYH11 expression across experimental conditions or disease states.

How can MYH11 antibodies be utilized in studying vascular diseases and pathological conditions?

MYH11 antibodies serve as powerful tools for investigating vascular pathologies:

• Aortic Dissection and Aneurysm Research: MYH11 mutations have been implicated in thoracic aortic aneurysms and dissections. Immunostaining with MYH11 antibodies enables assessment of smooth muscle cell phenotypic changes in diseased vessel walls, including detection of dedifferentiation patterns associated with pathological remodeling.

• Atherosclerosis Studies: MYH11 antibodies help track the fate of smooth muscle cells during atherosclerotic plaque development, particularly their phenotypic switching and migration from media to intima during plaque formation.

• Vascular Development Analysis: During embryonic and postnatal development, MYH11 expression marks terminal differentiation of vascular smooth muscle cells. Antibody-based tracking enables detailed mapping of vascular maturation processes.

• Tumor Vasculature Characterization: MYH11 antibodies distinguish mature vessels from immature tumor vasculature, providing important prognostic and therapeutic targeting information in cancer research.

• Transplant Vasculopathy Assessment: In transplanted organs, MYH11 immunostaining helps evaluate chronic rejection by revealing changes in smooth muscle distribution and phenotype in affected vessels.

These applications demonstrate how MYH11 antibodies contribute to mechanistic understanding of vascular pathologies and potential therapeutic target identification .

What methodological approaches enable the use of MYH11 antibodies in animal models of disease?

Implementing MYH11 antibody studies in animal models requires specific methodological considerations:

• Cross-Reactivity Verification: Before extensive studies, verify antibody cross-reactivity with the species of interest. While many anti-human MYH11 antibodies cross-react with mouse and rat orthologs due to high sequence conservation, validation is essential .

• Tissue Preparation Optimization:

  • For murine models, perfusion fixation with 4% paraformaldehyde generally provides superior morphology for vascular studies

  • Small animal vessels may require modified processing protocols with shorter fixation times

  • Consider specialized embedding techniques (e.g., vertical orientation of vessels) to obtain optimal cross-sections

• Background Reduction Strategies:

  • For mouse tissues, use mouse-on-mouse blocking kits when working with mouse monoclonal antibodies

  • Implement biotin/avidin blocking when using biotin-based detection systems

  • Extended serum blocking (2+ hours) often improves signal-to-noise ratio

• Genetically Modified Models:

  • MYH11-Cre transgenic mice enable smooth muscle-specific genetic manipulations

  • These models can provide excellent controls for antibody validation

  • Tissues from MYH11 knockout models serve as negative controls for specificity validation

• XenoMouse Applications:

  • XenoMouse II models that produce human antibodies in response to antigenic challenge offer unique opportunities to study human antibody responses in vivo

  • These models have been successfully used for studying human autoantibody diseases and could potentially be applied to vascular pathology research

These approaches optimize detection sensitivity and specificity while enabling complex experimental designs in disease modeling.

How do MYH11 antibodies compare to other smooth muscle markers in research applications?

Comparative analysis of MYH11 with other smooth muscle markers informs optimal experimental design:

For comprehensive smooth muscle cell characterization, researchers often implement multi-marker approaches:

• Combine MYH11 (high specificity) with α-SMA (high sensitivity) for complete SMC detection

• Use temporal marker panels to investigate differentiation states

• Apply marker combinations to distinguish SMCs from phenotypically similar cells (myofibroblasts, pericytes)

This comparative approach enables precise cellular identification across developmental stages and pathological conditions.

How should researchers interpret heterogeneous MYH11 staining patterns in tissue samples?

Heterogeneous MYH11 expression patterns require nuanced interpretation strategies:

• Physiological Heterogeneity: Different vascular beds naturally exhibit varying MYH11 expression levels. Large elastic arteries typically show stronger expression than smaller resistance vessels or veins. This physiological variation should not be misinterpreted as pathological.

• Cellular Differentiation States: Within a single vessel, heterogeneous MYH11 expression may indicate varying states of smooth muscle cell differentiation or phenotypic modulation. Correlate with proliferation markers (Ki-67) or synthetic phenotype markers to distinguish dedifferentiation from other causes of reduced expression.

• Technical vs. Biological Variability: Before attributing heterogeneity to biological phenomena, rule out technical factors:

  • Fixation gradients within tissue blocks

  • Antigen retrieval inconsistencies across the tissue section

  • Antibody penetration limitations in larger specimens

• Quantification Approaches for Heterogeneous Samples:

  • Report both the percentage of positive cells and the range of staining intensities

  • Consider area-weighted analysis when examining structures with varying cross-sectional areas

  • Implement hot-spot analysis for regions of interest showing distinct patterns

• Contextual Interpretation: Integrate MYH11 expression patterns with other markers and morphological features to develop comprehensive interpretations. For example, areas of low MYH11 expression adjacent to vascular injury may represent dedifferentiated smooth muscle cells participating in repair processes.

This multifaceted approach transforms complex staining patterns into biologically meaningful insights about smooth muscle cell states and vascular physiology.

What approaches can resolve contradictory results between different detection methods for MYH11?

When faced with discrepancies between different MYH11 detection methodologies, systematic troubleshooting is essential:

• Epitope Accessibility Differences:

  • Western blot denatures proteins, exposing epitopes that may be masked in fixed tissues

  • IHC preserves spatial information but may suffer from limited antibody penetration

  • Solution: Compare antibodies targeting different MYH11 epitopes across methods

• Isoform-Specific Detection:

  • MYH11 has multiple splice variants with tissue-specific expression patterns

  • Different antibodies may preferentially detect specific isoforms

  • Solution: Verify which isoforms are recognized by each antibody; use RT-PCR to identify expressed isoforms in your sample

• Sensitivity Thresholds:

  • Western blot can detect low abundance proteins throughout tissue homogenates

  • IHC may miss sparse expression but preserves localization information

  • Solution: Implement more sensitive detection methods (TSA amplification for IHC, chemiluminescent detection for WB)

• Quantification Standardization:

  • Establish equivalent quantification approaches across methods

  • Use recombinant MYH11 standards for calibration when possible

  • Normalize to appropriate controls specific to each methodology

• Orthogonal Validation:

  • Implement mRNA detection methods (in situ hybridization, qPCR) to corroborate protein findings

  • Consider mass spectrometry-based protein identification for definitive validation

  • Use genetic models (knockout/knockdown) to establish baseline negative controls

These approaches transform seemingly contradictory results into complementary data points that collectively provide more comprehensive insights into MYH11 biology.

How can researchers differentiate between MYH11 expression changes due to pathology versus technical artifacts?

Distinguishing genuine biological phenomena from technical variability requires systematic evaluation:

• Internal Control Assessment:

  • Examine MYH11 staining in unaffected tissues within the same section

  • Consistent staining in normal structures suggests changes in diseased areas are biologically meaningful

  • Generalized staining alterations across all tissues suggest technical issues

• Technical Replication:

  • Process multiple sections from the same sample using identical protocols

  • Variable results suggest technical inconsistency

  • Implement automated staining platforms when possible to enhance reproducibility

• Biological Replication:

  • Analyze multiple independent samples from the same condition

  • True pathological changes should be consistently observed across biological replicates

  • Calculate statistical measures of variability to quantify consistency

• Method Triangulation:

  • Verify key findings using at least two independent methodologies (e.g., IHC and Western blot)

  • Corroborate protein findings with mRNA expression data

  • Consider functionality assays to confirm physiological relevance of observed changes

• Control Experiments:

  • Include sample processing controls (fixation time series, antigen retrieval gradients)

  • Implement isotype controls to assess non-specific binding contributions

  • Use genetic models (when available) as definitive positive/negative controls